Monopar Therapeutics (MNPR) Earnings Date & Reports

A.I. Advisor

published Earnings

MNPR is expected to report earnings to fall 81.00% to -9 cents per share on November 07

Monopar Therapeutics MNPR Stock Earnings Reports

Q3'24

Est.

$-0.09

Q2'24

Missed

by $0.41

Q1'24

Beat

by $0.04

Q4'23

Beat

by $0.04

Q3'23

Est.

$-0.14

The last earnings report on August 09 showed earnings per share of -50 cents, missing the estimate of -9 cents. With 1.41M shares outstanding, the current market capitalization sits at 23.83M.

View a ticker or compare two or three

Compare

MNPR

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For MNPR
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company, which engages in building a drug development pipeline of oncology therapeutics in late preclinical and clinical development stages

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

1000 Skokie Boulevard

Phone

+1 847 388-0349

Employees

Web

https://www.monopartx.com